Cellectis S.A. Company Profile (NASDAQ:CLLS)

About Cellectis S.A.

Cellectis S.A. logoCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLLS
  • CUSIP:
Key Metrics:
  • Previous Close: $22.40
  • 50 Day Moving Average: $19.33
  • 200 Day Moving Average: $21.10
  • 52-Week Range: $16.09 - $34.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.95
  • P/E Growth: 0.00
  • Market Cap: $791.46M
  • Outstanding Shares: 35,333,000
  • Beta: 2.22
Profitability:
  • Net Margins: -59.01%
  • Return on Equity: -15.67%
  • Return on Assets: -12.38%
Debt:
  • Current Ratio: 5.08%
  • Quick Ratio: 5.08%
Additional Links:
Companies Related to Cellectis S.A.:

Analyst Ratings

Consensus Ratings for Cellectis S.A. (NASDAQ:CLLS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $46.60 (108.04% upside)

Analysts' Ratings History for Cellectis S.A. (NASDAQ:CLLS)
Show:
DateFirmActionRatingPrice TargetDetails
11/24/2016Piper Jaffray CompaniesSet Price TargetBuy$41.00View Rating Details
9/14/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$65.00View Rating Details
9/9/2016Jefferies Group LLCReiterated RatingBuy$47.00View Rating Details
4/5/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$45.00View Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$35.00View Rating Details
7/20/2015Bank of America CorpInitiated CoverageBuy$50.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Cellectis S.A. (NASDAQ:CLLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2016Q116($0.35)($0.53)ViewN/AView Earnings Details
3/16/2016Q415($0.30)$0.65ViewN/AView Earnings Details
11/19/2015Q215($0.43)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectis S.A. (NASDAQ:CLLS)
Current Year EPS Consensus Estimate: $-1.90 EPS
Next Year EPS Consensus Estimate: $-1.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.43)($0.50)
Q2 20163($0.65)($0.44)($0.55)
Q3 20163($0.90)($0.58)($0.71)
Q4 20163($0.65)($0.45)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cellectis S.A. (NASDAQ:CLLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectis S.A. (NASDAQ:CLLS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Cellectis S.A. (NASDAQ:CLLS)
DateHeadline
finance.yahoo.com logoAcorda (ACOR) Reports Narrower-than-Expected Loss in Q4 (NASDAQ:CLLS)
finance.yahoo.com - February 16 at 10:59 AM
News IconBio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More (NASDAQ:CLLS)
www.xconomy.com - February 10 at 4:37 PM
nasdaq.com logoWill Cellectis (CLLS) Continue to Surge Higher? - Nasdaq (NASDAQ:CLLS)
www.nasdaq.com - February 10 at 4:37 PM
finance.yahoo.com logoWill Cellectis (CLLS) Continue to Surge Higher? (NASDAQ:CLLS)
finance.yahoo.com - February 10 at 4:37 PM
marketexclusive.com logoCellectis SA (ADR) (NASDAQ:CLLS) Just Made A Big Step Forward In CAR-T (NASDAQ:CLLS)
marketexclusive.com - February 7 at 10:28 PM
thestreet.com logoCellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment (NASDAQ:CLLS)
us.rd.yahoo.com - February 7 at 5:24 PM
us.rd.yahoo.com logoCellectis Blood Cancer Gets FDA Nod for Trial (NASDAQ:CLLS)
us.rd.yahoo.com - February 7 at 5:24 PM
us.rd.yahoo.com logoCellectis SA (ADR) (CLLS) Just Made A Big Step Forward In CAR-T (NASDAQ:CLLS)
us.rd.yahoo.com - February 7 at 5:24 PM
uk.finance.yahoo.com logoCellectis to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:30 p.m. ET in New York (NASDAQ:CLLS)
uk.finance.yahoo.com - February 7 at 5:24 PM
nasdaq.com logoCellectis (CLLS) Shows Strength: Stock Moves 9.1% Higher - Nasdaq (NASDAQ:CLLS)
www.nasdaq.com - February 7 at 2:25 AM
News IconCellectis preps for groundbreaking US trials for an off-the-shelf CAR-T therapy (NASDAQ:CLLS)
endpts.com - February 6 at 9:24 PM
uk.finance.yahoo.com logoFDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S. (NASDAQ:CLLS)
us.rd.yahoo.com - February 6 at 9:24 PM
News IconSell-side is Weighing in on Cellectis SA (ADR) (NASDAQ:CLLS) Earnings & Targets - Aiken Advocate (NASDAQ:CLLS)
aikenadvocate.com - February 3 at 9:37 PM
News IconCellectis SA (CLLS) Updated Broker Ratings - NewsDen (NASDAQ:CLLS)
newsden.net - February 3 at 9:37 PM
finance.yahoo.com logoCellectis: Four Prominent Physicians to Join Cellectis Clinical Advisory Board (NASDAQ:CLLS)
finance.yahoo.com - January 23 at 4:36 PM
uk.finance.yahoo.com logoCellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions (NASDAQ:CLLS)
us.rd.yahoo.com - January 23 at 5:20 AM
News IconUpside Alert: Delving into Shares of Cellectis S.A. (NASDAQ:CLLS) - Prospect Journal (NASDAQ:CLLS)
prospectjournal.com - January 16 at 9:23 PM
News IconLive Chart Pattern Coverage: Will Cellectis SA (ADR) Short Squeeze Soon? The Stock Formed a Bearish Multiple ... - The Herald Beacon (NASDAQ:CLLS)
heraldbeacon.com - January 14 at 4:24 PM
publicnow.com logoCellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN (NASDAQ:CLLS)
us.rd.yahoo.com - January 3 at 11:07 PM
uk.finance.yahoo.com logoCellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT (NASDAQ:CLLS)
uk.finance.yahoo.com - January 3 at 6:05 PM
News IconWhy Cellectis (CLLS) Stock Might be a Great Pick - Yahoo Sports (NASDAQ:CLLS)
sports.yahoo.com - January 1 at 4:20 PM
finance.yahoo.com logoWhy Cellectis (CLLS) Stock Might be a Great Pick (NASDAQ:CLLS)
finance.yahoo.com - December 30 at 4:44 PM
News IconAre There Catalysts to Propel This Stock Forward: Cellectis S.A. (NASDAQ:CLLS) - Prospect Journal (NASDAQ:CLLS)
prospectjournal.com - December 27 at 12:17 PM
publicnow.com logoCellectis Announces Conference Call To Discuss Recent Recombinant DNA Advisory Committee (RAC) Meeting (NASDAQ:CLLS)
www.publicnow.com - December 16 at 9:46 PM
finance.yahoo.com logoBlog Coverage Repligen Acquires Maker of Tangential Flow Filtration Cassettes (NASDAQ:CLLS)
finance.yahoo.com - December 16 at 4:43 PM
News IconCellectis S.A. (CLLS) Valuation According To Analysts - UK Market News (NASDAQ:CLLS)
www.ukmarketnews.co.uk - December 16 at 2:46 AM
uk.finance.yahoo.com logoCellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN (NASDAQ:CLLS)
us.rd.yahoo.com - December 15 at 9:46 PM
us.rd.yahoo.com logo5:04 pm Cellectis announces recombinant DNA Advisory Committee's (:RAC) unanimous approval of UCART123 Phase 1 study protocols in AML and BPDCN (NASDAQ:CLLS)
us.rd.yahoo.com - December 15 at 9:46 PM
capitalcube.com logoETFs with exposure to Cellectis SA : December 12, 2016 (NASDAQ:CLLS)
www.capitalcube.com - December 12 at 4:37 PM
insidermonkey.com logoDo Hedge Funds Love Cellectis SA (ADR) (CLLS)? - Insider Monkey (blog) (NASDAQ:CLLS)
www.insidermonkey.com - December 12 at 12:28 PM
News IconDo Hedge Funds Love Cellectis SA (ADR) (CLLS)? (NASDAQ:CLLS)
feedproxy.google.com - December 10 at 7:30 PM
capitalcube.com logoCellectis SA :CLLS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:CLLS)
www.capitalcube.com - November 30 at 8:31 AM
capitalcube.com logoETFs with exposure to Cellectis SA : November 29, 2016 (NASDAQ:CLLS)
www.capitalcube.com - November 30 at 8:31 AM
businesswire.com logoCellectis Reports Financial Results for 3 rd Quarter and First Nine Months 2016 - Business Wire (press release) (NASDAQ:CLLS)
www.businesswire.com - November 22 at 9:56 PM
sg.finance.yahoo.com logoCellectis reports 3Q loss (NASDAQ:CLLS)
sg.finance.yahoo.com - November 22 at 9:56 PM
publicnow.com logoCellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016 (NASDAQ:CLLS)
www.publicnow.com - November 22 at 9:56 PM
publicnow.com logo3rd Quarter and First Nine Months 2016 Financial Results (NASDAQ:CLLS)
www.publicnow.com - November 22 at 9:56 PM
uk.finance.yahoo.com logoCellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY (NASDAQ:CLLS)
uk.finance.yahoo.com - November 21 at 10:17 PM
News IconInvestor's Buzzer – Cellectis S.A.'s (CLLS) - Hot Stocks Point (NASDAQ:CLLS)
www.hotstockspoint.com - November 18 at 8:34 PM
investorplace.com logoBiggest Movers in Manufacturing Stocks Now - CRDS CLLS FOSL CARA - Investorplace.com (NASDAQ:CLLS)
investorplace.com - November 16 at 4:16 PM
publicnow.com logoCellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123 (NASDAQ:CLLS)
www.publicnow.com - November 15 at 10:32 PM
News IconLatest Analyst Consensus For Cellectis S.A. (NASDAQ:CLLS) - UK Market News (NASDAQ:CLLS)
www.ukmarketnews.co.uk - November 15 at 9:17 AM
News IconLatest Analyst Reports On Cellectis S.A. - NewsDen (NASDAQ:CLLS)
newsden.net - November 13 at 5:49 PM
News IconLooking Ahead for Cellectis SA (ADR) (NASDAQ:CLLS); Are These Shares Ready to Go Higher? - CSZ News (NASDAQ:CLLS)
cincysportszone.com - November 10 at 3:43 PM
News IconCellectis S.A. (NASDAQ:CLLS) Latest Broker Coverage - NewsDen (NASDAQ:CLLS)
newsden.net - November 9 at 10:41 PM
businesswire.com logoCellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting (NASDAQ:CLLS)
www.businesswire.com - November 7 at 10:57 PM
News IconShares Knocked Down Over Past Month: Cellectis S.A. (NASDAQ:CLLS) - CSZ News (NASDAQ:CLLS)
cincysportszone.com - November 6 at 4:33 PM
News IconRecently Changed Price Targets On Cellectis S.A. (CLLS) - NewsDen (NASDAQ:CLLS)
newsden.net - November 5 at 11:48 AM
publicnow.com logoCellectis Hosts World’s First Gene Edited Dinner in NYC (NASDAQ:CLLS)
www.publicnow.com - November 1 at 8:26 AM
News IconStock Tracker: Earnings & Estimates for Cellectis SA (ADR) (NASDAQ:CLLS) - CSZ News (NASDAQ:CLLS)
cincysportszone.com - October 27 at 8:46 AM

Social

What is Cellectis S.A.'s stock symbol?

Cellectis S.A. trades on the NASDAQ under the ticker symbol "CLLS."

Where is Cellectis S.A.'s stock going? Where will Cellectis S.A.'s stock price be in 2017?

5 analysts have issued 12 month price objectives for Cellectis S.A.'s shares. Their forecasts range from $35.00 to $65.00. On average, they anticipate Cellectis S.A.'s share price to reach $46.60 in the next twelve months.

Who owns Cellectis S.A. stock?

Cellectis S.A.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (9.99%), Orbimed Advisors LLC (0.99%), Franklin Resources Inc. (0.69%), Ellington Management Group LLC (0.04%) and Fiera Capital Corp (0.03%).

Who bought Cellectis S.A. stock? Who is buying Cellectis S.A. stock?

Cellectis S.A.'s stock was purchased by a variety of institutional investors in the last quarter, including Ellington Management Group LLC and FMR LLC.

How do I buy Cellectis S.A. stock?

Shares of Cellectis S.A. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cellectis S.A. stock cost?

One share of Cellectis S.A. stock can currently be purchased for approximately $22.40.

Cellectis S.A. (NASDAQ:CLLS) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cellectis S.A. (NASDAQ:CLLS)

Earnings History Chart

Earnings by Quarter for Cellectis S.A. (NASDAQ:CLLS)

Dividend History Chart

Dividend Payments by Quarter for Cellectis S.A. (NASDAQ:CLLS)

Last Updated on 2/21/2017 by MarketBeat.com Staff